Chemours (NYSE:CC) Stock Gets Downgrade from Zacks Research

Posted by George Bondi on Nov 6th, 2026

Chemours (NYSE:CC – Get Free Report) was downgraded by stock analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report issued on Wednesday, Zacks reports.

Several other research analysts have also commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Chemours in a research report on Tuesday. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $16.00 price objective on shares of Chemours in a research note on Friday, October 9th. JPMorgan Chase & Co. cut their price objective on Chemours from $22.00 to $15.00 and set a “neutral” rating on the stock in a report on Thursday, August 13th. Barclays began coverage on Chemours in a research note on Monday, October 12th. They set an “equal weight” rating and a $16.00 target price on the stock. Finally, BMO Capital Markets lowered their target price on Chemours from $26.00 to $18.00 and set an “outperform” rating for the company in a report on Thursday, August 13th. Three investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $17.45.

Get Our Latest Stock Report on CC

Chemours Stock Performance

NYSE:CC opened at $12.77 on Wednesday. The company has a debt-to-equity ratio of 24.25, a quick ratio of 0.88 and a current ratio of 1.81. The stock has a market capitalization of $1.92 billion, a P/E ratio of -12.51 and a beta of 1.47. The company has a 50 day moving average price of $14.02 and a 200 day moving average price of $18.23. Chemours has a fifty-two week low of $10.44 and a fifty-two week high of $28.67.

Chemours (NYSE:CC – Get Free Report) last posted its earnings results on Monday, November 2nd. The specialty chemicals company reported $0.21 earnings per share for the quarter, missing the consensus estimate of $0.26 by ($0.05). The company had revenue of $1.54 billion during the quarter, compared to analyst estimates of $1.53 billion. Chemours had a negative net margin of 2.64% and a positive return on equity of 76.52%. The firm’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter last year, the business posted $0.40 EPS. Equities research analysts forecast that Chemours will post 0.81 EPS for the current year.

Insider Activity at Chemours

In other Chemours news, CEO Denise Dignam purchased 3,378 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was bought at an average price of $14.95 per share, with a total value of $50,501.10. Following the transaction, the chief executive officer directly owned 339,916 shares of the company’s stock, valued at approximately $5,081,744.20. This represents a 1.00% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Calderon Gerardo Familiar purchased 1,935 shares of the company’s stock in a transaction on Wednesday, August 12th. The stock was acquired at an average price of $15.53 per share, with a total value of $30,050.55. Following the purchase, the insider owned 58,547 shares of the company’s stock, valued at approximately $909,234.91. This represents a 3.42% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 0.85% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Maryland State Retirement & Pension System raised its position in Chemours by 53.7% in the 3rd quarter. Maryland State Retirement & Pension System now owns 33,631 shares of the specialty chemicals company’s stock valued at $456,000 after purchasing an additional 11,752 shares in the last quarter. Jefferies Financial Group Inc. boosted its stake in shares of Chemours by 251.8% in the 3rd quarter. Jefferies Financial Group Inc. now owns 2,742,068 shares of the specialty chemicals company’s stock valued at $37,210,000 after buying an additional 1,962,523 shares during the period. Parallel Advisors LLC boosted its stake in shares of Chemours by 15.1% in the 3rd quarter. Parallel Advisors LLC now owns 5,926 shares of the specialty chemicals company’s stock valued at $80,000 after buying an additional 776 shares during the period. Pekin Hardy Strauss Inc. grew its position in shares of Chemours by 150.6% during the third quarter. Pekin Hardy Strauss Inc. now owns 201,082 shares of the specialty chemicals company’s stock worth $2,729,000 after buying an additional 120,832 shares in the last quarter. Finally, Chicago Partners Investment Group LLC acquired a new position in shares of Chemours during the third quarter worth about $443,000. 76.26% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Chemours

Here are the key news stories impacting Chemours this week:

Positive Sentiment: Chemours launched Faizeon two-phase liquid-cooling solutions for AI data centers, designed to improve cooling efficiency and reduce water use. The product positions the company to pursue demand from expanding data-center infrastructure, though the reports do not quantify expected sales or financial impact. Article: CC Launches Faizeon Cooling Solutions to Meet AI Data Center Demand
Neutral Sentiment: Barclays maintained its Hold rating, while another report described analyst views on Chemours as mixed, indicating no clear consensus signal from analysts. Article: Barclays Keeps Their Hold Rating on Chemours Article: Analysts’ Opinions Are Mixed
Negative Sentiment: Zacks Research downgraded Chemours from Hold to Strong Sell, a more bearish assessment that may add pressure to the shares. Zacks Research ratings
Negative Sentiment: Several law firms publicized a securities-fraud class action against Chemours and certain executives, with a December 7 lead-plaintiff deadline. The complaint alleges investors were misled about 2026 EBITDA guidance and Opteon refrigerant sales shifted into 2025 by distributor prebuying. These are allegations, not findings; the litigation nevertheless adds legal and reputational uncertainty. Article: Class action filing against Chemours

Chemours Company Profile

(Get Free Report)

The Chemours Company (NYSE: CC) is a global chemistry company that develops and manufactures performance chemicals and advanced materials for industrial and consumer applications. The company serves customers in markets including automotive, construction, energy, electronics, healthcare, and general manufacturing.

Chemours operates through businesses focused on Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. Its products include titanium dioxide pigments used to provide whiteness and opacity in coatings, plastics, and paper; refrigerants and related thermal-management solutions; and high-performance fluoropolymers and specialty materials sold under brands such as Teflon™, Viton™, and Nafion™.

Headquartered in Wilmington, Delaware, Chemours serves customers globally through manufacturing facilities, research and development operations, and commercial activities across North America, Latin America, Europe, and Asia-Pacific.